Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to...
Age: 18 years - 66+
Gender: All
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and
paclitaxel combination therapy in patients with relapsed or refractory extensive stage small
cell lung cancer.
Age: 18 years - 66+
Gender: All
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
This phase II/III trial examines whether patients who have undergone surgical removal of
bladder, but require an additional treatment called immunotherapy to help prevent their
bladder cancer from coming back, can be identified by a blood test. Many types of tumors ...
Age: 18 years - 66+
Gender: All
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
The goal of this clinical trial is to study the safety and tolerability in all advanced solid
tumors, including advanced urothelial carcinoma.
The main question[s] it aims to answer are:
- Is FX-909 safe and tolerable
- What is the right dose level for pat...
Age: 18 years - 66+
Gender: All
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the
bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study
will try to find out if the drugs disitamab vedotin with pembrolizumab works bet...
Age: 18 years - 66+
Gender: All
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT
monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as
first-line treatment, in participants with unresectable, locally advanced or metas...
Age: 18 years - 66+
Gender: All
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition
to standard of care chemotherapy versus standard of care chemotherapy alone in treating
patients with colorectal cancer that has spread to the liver (liver metastases) and ...
Age: 18 years - 66+
Gender: All
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of
danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line
treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients...
Age: 18 years - 66+
Gender: All
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767)
with two other medications called cemiplimab and chemotherapy, individually called a "study
drug" or collectively called "study drugs". 'Investigational' means that the study d...
Age: 18 years - 66+
Gender: All
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramuciruma...
Age: 18 years - 66+
Gender: All
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to evaluate the efficacy and safety of selinexor as a
maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a
partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Soli...
Age: 18 years - 66+
Gender: All
Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced
non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due
to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radi...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as
monotherapy or in combination with ultralow dose gemcitabine in participants with
platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma
ba...
Age: 18 years - 66+
Gender: All
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of:
- AB521 when taken alone in participants with advanced solid tumor malignancies and clear
cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- AB521 monotherapy and A...
Age: 18 years - 66+
Gender: All
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
The primary purpose of this study is to determine the safety and tolerability of the
combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2
dose (RP2D) when administered as first line (1L) treatment in participants with locally...
Age: 18 years - 66+
Gender: All
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in
patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to
other places in the body (metastatic), or cannot be removed by surgery (unresectable).
...
Age: 18 years - 66+
Gender: All
Pembrolizumab in Muscle-invasive Bladder Cancer
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing
schedules of cemiplimab given in combination with cisplatin and docetaxel induction
chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head ...
Age: 18 years - 66+
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All